請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58158
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊泮池(Pan-Chyr Yang) | |
dc.contributor.author | Wan-Jiun Chen | en |
dc.contributor.author | 陳菀均 | zh_TW |
dc.date.accessioned | 2021-06-16T08:07:08Z | - |
dc.date.available | 2017-10-09 | |
dc.date.copyright | 2014-10-09 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-06-12 | |
dc.identifier.citation | 1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013). 3. Herbst, R.S., Heymach, J.V. & Lippman, S.M. Lung cancer. N Engl J Med 359, 1367-1380 (2008). 4. McErlean, A. & Ginsberg, M.S. Epidemiology of lung cancer. Semin Roentgenol 46, 173-177 (2011). 5. Vineis, P. et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96, 99-106 (2004). 6. Sun, S., Schiller, J.H. & Gazdar, A.F. Lung cancer in never smokers--a different disease. Nat Rev Cancer 7, 778-790 (2007). 7. Hwang, S.J. et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 113, 238-243 (2003). 8. Sanders, B.M., Jay, M., Draper, G.J. & Roberts, E.M. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 60, 358-365 (1989). 9. Bell, D.W. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37, 1315-1316 (2005). 10. Bailey-Wilson, J.E. et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 75, 460-474 (2004). 11. Mao, L. et al. Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89, 857-862 (1997). 12. Spira, A. et al. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc Natl Acad Sci U S A 101, 10143-10148 (2004). 13. Sato, M., Shames, D.S., Gazdar, A.F. & Minna, J.D. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2, 327-343 (2007). 14. Beadsmoore, C.J. & Screaton, N.J. Classification, staging and prognosis of lung cancer. Eur J Radiol 45, 8-17 (2003). 15. Wistuba, II et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res 6, 2604-2610 (2000). 16. Thoracic Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 156, 320-332 (1997). 17. Pearlberg, J.L., Sandler, M.A., Lewis, J.W., Jr., Beute, G.H. & Alpern, M.B. Small-cell bronchogenic carcinoma: CT evaluation. AJR Am J Roentgenol 150, 265-268 (1988). 18. Hirsch, F.R. et al. Histopathologic classification of small cell lung cancer. Changing concepts and terminology. Cancer 62, 973-977 (1988). 19. Shin, M.S., Jackson, L.K., Shelton, R.W., Jr. & Greene, R.E. Giant cell carcinoma of the lung. Clinical and roentgenographic manifestations. Chest 89, 366-369 (1986). 20. Woodring, J.H. & Stelling, C.B. Adenocarcinoma of the lung: a tumor with a changing pleomorphic character. AJR Am J Roentgenol 140, 657-664 (1983). 21. Aoki, T. et al. Evolution of peripheral lung adenocarcinomas: CT findings correlated with histology and tumor doubling time. AJR Am J Roentgenol 174, 763-768 (2000). 22. Chaudhuri, M.R. Primary pulmonary cavitating carcinomas. Thorax 28, 354-366 (1973). 23. Kazerooni, E.A., Bhalla, M., Shepard, J.A. & McLoud, T.C. Adenosquamous carcinoma of the lung: radiologic appearance. AJR Am J Roentgenol 163, 301-306 (1994). 24. Travis, W.D. et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med 137, 668-684 (2013). 25. Austin, J.H. et al. Radiologic implications of the 2011 classification of adenocarcinoma of the lung. Radiology 266, 62-71 (2013). 26. Travis, W.D., Brambilla, E. & Riely, G.J. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 31, 992-1001 (2013). 27. Egeblad, M., Nakasone, E.S. & Werb, Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18, 884-901 (2010). 28. Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001). 29. McCarthy, N. Microenvironment: Enforced compliance. Nat Rev Cancer 12, 152-153 (2012). 30. Joyce, J.A. & Pollard, J.W. Microenvironmental regulation of metastasis. Nat Rev Cancer 9, 239-252 (2009). 31. Eramo, A., Haas, T.L. & De Maria, R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 29, 4625-4635 (2010). 32. Beck, B. & Blanpain, C. Unravelling cancer stem cell potential. Nat Rev Cancer 13, 727-738 (2013). 33. Kim, C.F. et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835 (2005). 34. Eramo, A. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15, 504-514 (2008). 35. Zhang, W.C. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259-272 (2012). 36. Yan, X. et al. Identification of CD90 as a marker for lung cancer stem cells in A549 and H446 cell lines. Oncol Rep 30, 2733-2740 (2013). 37. Levina, V., Marrangoni, A.M., DeMarco, R., Gorelik, E. & Lokshin, A.E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3, e3077 (2008). 38. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792 (2005). 39. Sequist, L.V., Bell, D.W., Lynch, T.J. & Haber, D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25, 587-595 (2007). 40. Schatton, T., Frank, N.Y. & Frank, M.H. Identification and targeting of cancer stem cells. Bioessays 31, 1038-1049 (2009). 41. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. Nat Rev Cancer 5, 275-284 (2005). 42. Gottesman, M.M., Fojo, T. & Bates, S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58 (2002). 43. Diessner, J. et al. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1). Cell death & disease 5, e1149 (2014). 44. Blatt, K. et al. Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q- Patients with MDS and AML. Clin Cancer Res 20, 1-14 (2014). 45. Albini, A. & Sporn, M.B. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 7, 139-147 (2007). 46. Ronnov-Jessen, L., Petersen, O.W. & Bissell, M.J. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiological reviews 76, 69-125 (1996). 47. Bremnes, R.M. et al. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 6, 209-217 (2011). 48. De Wever, O., Demetter, P., Mareel, M. & Bracke, M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 123, 2229-2238 (2008). 49. Sato, N., Maehara, N. & Goggins, M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 64, 6950-6956 (2004). 50. Boire, A. et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (2005). 51. Mueller, M.M. & Fusenig, N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4, 839-849 (2004). 52. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348 (2005). 53. Franco, O.E. et al. Altered TGF-beta signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res 71, 1272-1281 (2011). 54. Sneddon, J.B. & Werb, Z. Location, location, location: the cancer stem cell niche. Cell Stem Cell 1, 607-611 (2007). 55. Fuchs, E., Tumbar, T. & Guasch, G. Socializing with the neighbors: stem cells and their niche. Cell 116, 769-778 (2004). 56. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006). 57. Williams, R.L. et al. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336, 684-687 (1988). 58. Ling, T.Y. et al. Identification of pulmonary Oct-4+ stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS-CoV) infection in vitro. Proc Natl Acad Sci U S A 103, 9530-9535 (2006). 59. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat Rev Cancer 6, 392-401 (2006). 60. Kojima, Y. et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A 107, 20009-20014 (2010). 61. Barone, I. et al. Leptin Mediates Tumor-Stromal Interactions That Promote the Invasive Growth of Breast Cancer Cells. Cancer Res (2012). 62. Malanchi, I. et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481, 85-89 (2012). 63. Thiery, J.P., Acloque, H., Huang, R.Y. & Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009). 64. Kalluri, R. & Weinberg, R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420-1428 (2009). 65. Rosenstraus, M.J., Sterman, B., Carr, A. & Brand, L. Fibroblast feeder layers inhibit differentiation of retinoic acid-treated embryonal carcinoma cells by increasing the probability of stem cell renewal. Exp Cell Res 152, 378-389 (1984). 66. Liao, C.P., Adisetiyo, H., Liang, M. & Roy-Burman, P. Cancer-associated fibroblasts enhance the gland-forming capability of prostate cancer stem cells. Cancer Res 70, 7294-7303 (2010). 67. Kinugasa, Y., Matsui, T. & Takakura, N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 32, 145-156 (2014). 68. Yu, Y. et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer 110, 724-732 (2014). 69. Hasegawa, T. et al. Cancer-associated fibroblasts might sustain the stemness of scirrhous gastric cancer cells via transforming growth factor-beta signaling. Int J Cancer 134, 1785-1795 (2014). 70. Ho, M.M., Ng, A.V., Lam, S. & Hung, J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67, 4827-4833 (2007). 71. Bertolini, G. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106, 16281-16286 (2009). 72. Sullivan, J.P. et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70, 9937-9948 (2010). 73. Vermeulen, L. et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 105, 13427-13432 (2008). 74. Vermeulen, L., Sprick, M.R., Kemper, K., Stassi, G. & Medema, J.P. Cancer stem cells--old concepts, new insights. Cell Death Differ 15, 947-958 (2008). 75. Cirri, P. & Chiarugi, P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 31, 195-208 (2012). 76. Sugimoto, H., Mundel, T.M., Kieran, M.W. & Kalluri, R. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5, 1640-1646 (2006). 77. Nazareth, M.R. et al. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 178, 5552-5562 (2007). 78. Shieh, A.C., Rozansky, H.A., Hinz, B. & Swartz, M.A. Tumor cell invasion is promoted by interstitial flow-induced matrix priming by stromal fibroblasts. Cancer Res 71, 790-800 (2011). 79. Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316, 1324-1331 (2010). 80. Ostman, A. & Augsten, M. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev 19, 67-73 (2009). 81. Barcellos-Hoff, M.H., Lyden, D. & Wang, T.C. The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13, 511-518 (2013). 82. Liu, S. et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71, 614-624 (2011). 83. Barone, I. et al. Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res 72, 1416-1427 (2012). 84. Giannoni, E. et al. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 70, 6945-6956 (2010). 85. Tirino, V. et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J 27, 13-24 (2013). 86. Filatova, A., Acker, T. & Garvalov, B.K. The cancer stem cell niche(s): The crosstalk between glioma stem cells and their microenvironment. Biochim Biophys Acta 1830, 2496-2508 (2013). 87. Navab, R. et al. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A 108, 7160-7165 (2011). 88. Tesei, A. et al. Isolation of stem/progenitor cells from normal lung tissue of adult humans. Cell Prolif 42, 298-308 (2009). 89. Gangemi, R.M. et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27, 40-48 (2009). 90. Chiou, S.H. et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 70, 10433-10444 (2010). 91. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648 (1994). 92. Visvader, J.E. & Lindeman, G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8, 755-768 (2008). 93. Mitra, S., Stemke-Hale, K., Mills, G.B. & Claerhout, S. Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. Cancer Sci 103, 400-407 (2012). 94. Vaiopoulos, A.G., Kostakis, I.D., Koutsilieris, M. & Papavassiliou, A.G. Colorectal cancer stem cells. Stem Cells 30, 363-371 (2012). 95. Keysar, S.B. & Jimeno, A. More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 9, 2450-2457 (2010). 96. Hill, R.P. & Perris, R. 'Destemming' cancer stem cells. J Natl Cancer Inst 99, 1435-1440 (2007). 97. Takebe, N., Harris, P.J., Warren, R.Q. & Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8, 97-106 (2011). 98. Visvader, J.E. Cells of origin in cancer. Nature 469, 314-322 (2011). 99. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 17, 1253-1270 (2003). 100. Goodell, M.A., Brose, K., Paradis, G., Conner, A.S. & Mulligan, R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183, 1797-1806 (1996). 101. Ginestier, C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567 (2007). 102. Magee, J.A., Piskounova, E. & Morrison, S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012). 103. Battula, V.L. et al. Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells. Stem Cells 28, 1435-1445 (2010). 104. Acosta, J.C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006-1018 (2008). 105. Zuo, J. et al. Novel Polypyridyl chelators deplete cellular zinc and destabilize the X-linked inhibitor of apoptosis protein (XIAP) prior to induction of apoptosis in human prostate and breast cancer cells. J Cell Biochem 113, 2567-2575 (2012). 106. Wielenga, V.J. et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154, 515-523 (1999). 107. Chang, C.J. et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 13, 317-323 (2011). 108. Mani, S.A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008). 109. Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779 (2009). 110. Shan, J. et al. Nanog regulates self-renewal of cancer stem cell through IGF pathway in human hepatocellular carcinoma. Hepatology 56, 1004-1014 (2012). 111. Doedens, A.L. et al. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res 70, 7465-7475 (2010). 112. Xu, Y., Hu, Y.D., Zhou, J. & Zhang, M.H. Establishing a lung cancer stem cell culture using autologous intratumoral fibroblasts as feeder cells. Cell Biol Int 35, 509-517 (2011). 113. Mannello, F. & Tonti, G.A. Concise review: no breakthroughs for human mesenchymal and embryonic stem cell culture: conditioned medium, feeder layer, or feeder-free; medium with fetal calf serum, human serum, or enriched plasma; serum-free, serum replacement nonconditioned medium, or ad hoc formula? All that glitters is not gold! Stem Cells 25, 1603-1609 (2007). 114. Hanahan, D. & Coussens, L.M. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322 (2012). 115. Bendall, S.C. et al. IGF and FGF cooperatively establish the regulatory stem cell niche of pluripotent human cells in vitro. Nature 448, 1015-1021 (2007). 116. Vermeulen, L., de Sousa e Melo, F., Richel, D.J. & Medema, J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 13, e83-89 (2012). 117. Bjornson, C.R., Rietze, R.L., Reynolds, B.A., Magli, M.C. & Vescovi, A.L. Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 283, 534-537 (1999). 118. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-872 (2007). 119. Schwitalla, S. et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 152, 25-38 (2013). 120. Cardillo, T.M., Trisal, P., Arrojo, R., Goldenberg, D.M. & Chang, C.H. Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer 13, 170 (2013). 121. Spiliotaki, M. et al. Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Lung Cancer 73, 158-165 (2011). 122. Zeng, X., Zhang, H., Oh, A., Zhang, Y. & Yee, D. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor. Breast Cancer Res Treat 133, 117-126 (2012). 123. Tap, W.D. et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol 30, 1849-1856 (2012). 124. Strosberg, J.R. et al. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer 20, 383-390 (2013). 125. de Bono, J.S. et al. figitumumab. Clin Cancer Res 20, 1925-1934 (2014). 126. Abou-Alfa, G.K. et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 60, 319-324 (2014). 127. Ekman, S. et al. Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol 50, 441-447 (2011). 128. Ozkan, E.E. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 344, 1-24 (2011). 129. Schmitz, S. et al. Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02). Ann Oncol 23, 2153-2161 (2012). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58158 | - |
dc.description.abstract | 無論在台灣或全世界,肺癌是占癌症死亡的首位。縱使許多治療方法以及新藥的出現能夠提高肺癌病人之存活率,然而其病人的癒後仍是相當不好。近年來研究指出癌症幹細胞被認為是腫瘤在經過化學治療後具有藥物抗藥性以及具有復發成為新的腫瘤之細胞群。癌症被認為像是一個器官,其組成包含不同種類之細胞群起源自其幹細胞,此幹細胞被稱為癌症幹細胞。癌症幹細胞被認為類似幹細胞具有幹性(stemness),意指其具有維持自我更新和分化為不同特異種類細胞之能力。此概念源自於惡性血液疾病但最近也被落實於固態腫瘤當中,其中也包括我們所研究的主題-肺癌。
癌症幹細胞被認為是治療癌症重要的標靶細胞,然而在腫瘤微環境中癌症幹細胞如何維持其幹性目前仍然不清楚。因此找出維持癌症幹細胞能力以及建立體外培養系統是極需研究之課題。本研究結果證明藉由腫瘤的微環境中的癌相關纖維母細胞(cancer-associated fibroblasts, CAFs),透過旁泌素(paracrine)機制分泌IGF-II、HGF及SDF1作用於癌症幹細胞相對應之接受體IGF1R、Met及CXCR4可以維持癌症幹細胞特性及促進癌症幹細胞生長。有趣且其具應用價值的是藉由標靶之抗體或抑制劑阻斷旁泌素(paracrine)機制之訊息傳遞路徑可以有效抑制肺癌幹細胞之能力阻止腫瘤之生長。本研究也進一步利用臨床檢體分析發現其中癌相關纖維母細胞之IGF-II和表現於肺癌細胞之IGF1R、Nanog與病人癒後及復發有顯著之相關。本研究發現癌相關纖維母細胞為支持細胞幹性之利基(Niche),阻斷癌症幹細胞以及癌相關纖維母細胞之旁泌素(paracrine)機制可作為臨床治療肺癌幹細胞的方法。 | zh_TW |
dc.description.abstract | Lung cancer is the leading cause of cancer death in Taiwan and worldwide. After a lot of efforts for improving the survival, the prognosis remained bad. Recently, cancer stem cells (CSCs) theory is proposed for an intrinsic resistance of tumor to chemotherapy. Cancer is regarded as an organ because of hierarchically organized heterogeneous populations of cells and possible originate from its stem cells “cancer stem cells”. CSCs can be viewed to have the ability “stemness” as stem cells with true multipotency and asymmetric division that maintain self-renewal and differentiate to specialized cell types. It is becoming increasingly clear that CSCs not only exist in hematologic malignancy but also in solid tumor including lung cancer. Cancer stem cells (CSCs) are the key target to cure cancer; however, how the CSCs subpopulation could be maintained and preserving their stemness in the tumorous microenvironment remains unknown. To establish a culture system for maintaining cancer stemness is urgently needed. Here, we demonstrated that cancer-associated fibroblasts (CAFs) can play as feeders with exhibiting significantly elevated paracrine IGF-II, HGF and SDF1 to enrich and maintain the cancer stemness and tumorigenecity of lung cancer cells synergistically through IGF1R, Met and CXCR4 that expressed in cancer cells. Interestingly and applicability, blockage of the paracrine signaling with specific antibody or inhibitors could inhibit Nanog expression, cancer stemness and tumor growth. The Cox regression analysis was performed to evaluate whether the IGF-II in CAFs; IGF1R and Nanog in cancer cells are independent prognostic factors. The Kaplan–Meier survival analysis was conducted to determine the association of the IGF-II, IGF1R and Nanog with overall survival and relapse-free survival. Our data demonstrate CAFs constitute the supporting niche for cancer stemness, and targeting this paracrine signaling may present a new therapeutic strategy for NSCLC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T08:07:08Z (GMT). No. of bitstreams: 1 ntu-103-D97443003-1.pdf: 9211512 bytes, checksum: 7481bd51326b5dea22b1f74d602e9816 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 誌謝-----------------------------------------------------i
中文摘要------------------------------------------------ ii Abstract-----------------------------------------------iii Contents-------------------------------------------------v List of Figures------------------------------------------i List of Tables------------------------------------------iv Chapter 1 Molecular Aspects of Stemness in Lung Cancer---1 1. Lung cancer-------------------------------------------1 1.1 Clinical outcome of Lung cancer----------------------1 1.2 Risk factors of lung cancer -------------------------1 1.3 Histological classification of lung cancer-----------3 2. Cancer stem cells-------------------------------------6 2.1 Tissue and tumor heterogeneity-----------------------6 2.2 Identification of cancer stem cells in lung cancer---6 2.3 Implication of cancer stem cells---------------------7 3. Cancer niche------------------------------------------9 3.1 Components of cancer niche---------------------------9 3.2 Cancer-associated fibroblast and carcinogenesis-----10 3.3 Cancer-associated fibroblast and cancer stemness----10 4. Motivation and purpose-------------------------------11 Chapter 2 Cancer associated fibroblasts as a niche for lung cancer stem cells---------------------------------------13 1. Summary----------------------------------------------13 2. Introduction-----------------------------------------14 3. Materials and Methods--------------------------------16 4. Results----------------------------------------------20 5. Discussions------------------------------------------21 Chapter 3 Identification and Characterization of lung cancer stem cells---------------------------------------22 1. Summary----------------------------------------------22 2. Introduction-----------------------------------------24 3. Materials and Methods--------------------------------25 4. Results----------------------------------------------33 5. Discussions------------------------------------------38 Chapter 4 Regulation mechanism between lung cancer stem cells and cancer associated fibroblasts-----------------40 1. Summary----------------------------------------------40 2. Introduction-----------------------------------------41 3. Materials and Methods--------------------------------43 4. Results----------------------------------------------53 5. Discussions------------------------------------------63 Figures-------------------------------------------------71 References---------------------------------------------143 Appendices---------------------------------------------152 | |
dc.language.iso | en | |
dc.title | 癌相關纖維母細胞調控肺癌幹性可塑性之研究 | zh_TW |
dc.title | Cancer-associated fibroblasts regulate the plasticity for lung cancer stemness | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 陳惠文(Huei-Wen Chen) | |
dc.contributor.oralexamcommittee | 鄭安理,劉扶東,陳健尉 | |
dc.subject.keyword | 肺癌,肺癌幹細胞,腫瘤微環境,癌相關纖維母細胞, | zh_TW |
dc.subject.keyword | lung cancer,cancer stem cell (CSC),tumor microenvironment,cancer associated fibroblasts (CAFs), | en |
dc.relation.page | 152 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-06-12 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 腫瘤醫學研究所 | zh_TW |
顯示於系所單位: | 腫瘤醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。